Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18388622 | 0.95 | SLC6A3 (0.38) | SLC6A3 | |
| SCHEMBL18883214 | 0.93 | SLC6A3 (0.37) | SLC6A3 | |
| SCHEMBL21689686 | 0.90 | — | — | |
| SCHEMBL21393127 | 0.87 | SLC6A3 (0.39) | SLC6A3 | |
| SCHEMBL9003787 | 0.81 | — | — | |
| SCHEMBL19426999 | 0.78 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL19957898 | 0.76 | — | — | |
| SCHEMBL18999679 | 0.76 | — | — | |
| SCHEMBL16187663 | 0.75 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL9340047 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | CFD, DDOST, HEXD | SLC6A3 1398/4885 |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | GLP1R, ADGRF1, CCKAR | SLC6A3 2150/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | SLC6A3 2431/4885 |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | CDK9, CDK19, CDK6 | SLC6A3 4293/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | SLC6A3 2431/4885 |
| US-20230348371-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | PYGB, ATP6V1B2, GLP1R | SLC6A3 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.